The new drug regulatory agency is coming! There are only 32 in the country

Medical Network March 15th The National Emblem is on, the stars are bright, one motion, the whole country. The electric light shines, the blast moves, the moment Luoyang paper is expensive, the country's great undertakings, worded words, the concept of impassioned passion.

After many years of the General Administration of Pharmacy and Drugs, the Health and Planning Commission, and the Medical Reform Office are gone! Soon after, if we see the new ministry issuing its first decree, we will surely be stunned - cut the time bar from this, half to memory, half to the future .

In the future, State Market Supervision Administration, National Health health The committee will undoubtedly be the protagonist of our focus. The 'Market Administration Bureau, the State Food and Drug Administration, the Weijian Committee' will be short for us to use frequently.

After the General Administration of Marketing came, what will it do? First look at the functions conferred by the State Council.

The "State Council Institutional Reform Program" integrates the responsibilities of the State Administration for Industry and Commerce, the State Administration of Quality Supervision, the General Administration of Food and Drug Control, the NDRC's price supervision and inspection and anti-monopoly enforcement duties, the Ministry of Commerce's anti-monopoly enforcement, and the State Council's anti-monopoly committee.

As an institution directly under the State Council, it undertakes unified anti-monopoly law enforcement. As a result, the anti-monopoly law enforcement functions originally dispersed in the National Development and Reform Commission, the Ministry of Commerce, and the State Administration for Industry and Commerce are integrated into the General Administration of Market Supervision. Anti-monopoly law enforcement will also end the 'Kowloon's water crisis.' situation.

Huibaichuan became a rapids, pouring away from the original on the grass; set firepower into a giant cannon, breaking the spring breeze and health.

In the past few years, the pharmaceutical industry has already become one of the key areas of national antitrust enforcement. For example, monopoly of raw materials: Among the 1600 kinds of APIs produced in China, many varieties are only individual enterprise With the production number, even if the number is more variety, there are few real production companies.

In recent years, some manufacturers or commercial companies have adopted a method of controlling the supply of all raw material medicines of a certain species, which has drastically increased the price of the products. According to the company's data, there are 20 raw material medicines whose price increase rate exceeds 5 times, with the largest increase being 70. Times, the current "profit model" coverage has expanded.

There were corporate feedbacks, and there were a total of 68 varieties of major price hikes for purchased bulk drugs. The price hikes involved the market monopolizing the control of sales of 42 varieties, and the company's stoppage of production and production led to tight supply of 12 varieties of the market, and the increase in production costs of 10 varieties. Other reasons 4 varieties.

In addition to this, there are also problems plaguing the industry's trusteeship and malicious control of sales. Bidding Wait.

Such as drug Centralized tendering: The excessive human intervention in the regulation has led to excessive administrative control. Currently, the bidding policies for medicines sponsored by local governments have been seriously deviated, and the dissimilation has become a disguised form of administrative examination and approval. This has led to areas such as local protection, regional blockade, administrative monopoly, and designated distribution bids. , Even commercial bribery and other issues.

The expectation is that with the concentration of anti-monopoly functions, the new medicine The anti-monopoly law enforcement work of the industry will also be greatly strengthened. In the future, more price monopoly in the pharmaceutical industry, exclusive distribution management, etc. will exclude other competitors' behaviors, or will be detected and punished.

There is also a new name that needs to be adapted - State Food and Drug Administration.

In contrast to the past, the State Food and Drug Administration is regulated by the General Administration of Marketing and is only set up at the provincial level. In other words, the food and drug administration departments at the county and city levels now have to take off their brands and enforce the law in the future. In the name of the regulatory authority, there are only 32 national food and drug administrations.

The news and analysis on the reform of the ministries and commissions over the past few days have largely centered on the specific functions of the General Administration of the Market, the State Food and Drug Administration, and the Health and Welfare Committee. It is about the context of everyone in the industry. I am afraid that we will not allow us to look forward to it for too long. There are detailed deployments and personnel appointments.

Wait for everyone.